Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pirfenidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 5/20 | 0.48 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.39 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.38 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.38 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.38 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.38 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.38 |
| ▸ | DDB1 known ✓ | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN known ✓ | Q96SW2 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | HPGD | P15428 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | COMT | P21964 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirfenidone SCHEMBL1006039 | 0.98 | KDM4E (1.00) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| Pirfenidone SCHEMBL4708 | 0.98 | KDM4E (1.00) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| Pirfenidone SCHEMBL28079090 | 0.96 | KDM4E (0.96) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| Pirfenidone SCHEMBL28532042 | 0.96 | KDM4E (0.96) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| Pirfenidone SCHEMBL28115013 | 0.89 | KDM4E (0.83) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| Pirfenidone SCHEMBL27872362 | 0.89 | ALDH1A1 (0.83) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| SCHEMBL356681 | 0.87 | ALDH1A1 (0.80) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| SCHEMBL10059357 | 0.87 | KDM4E (0.79) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| SCHEMBL3970272 | 0.85 | ALDH1A1 (0.77) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| Deupirfenidone SCHEMBL4059454 | 0.85 | KDM4E (0.76) | KDM4EALDH1A1CYP1A2HPGDBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114796122-B | Polydopamine-carrying pirfenidone nanoparticle and preparation method and application thereof | 山东大学 | 2023-03-24 | — | — | CN | claimed |
| CN-114796122-A | Polydopamine-carrying pirfenidone nanoparticle and preparation method and application thereof | 山东大学 | 2022-07-29 | — | — | CN | claimed |
| CN-114796122-B | Polydopamine-carrying pirfenidone nanoparticle and preparation method and application thereof | 山东大学 | 2023-03-24 | — | — | CN | disclosed |
| CN-115297886-A | IL-7R alpha binding compounds | 麦地金公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-114796122-A | Polydopamine-carrying pirfenidone nanoparticle and preparation method and application thereof | 山东大学 | 2022-07-29 | — | — | CN | disclosed |
| US-20210369693-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP | 2021-12-02 | — | — | US | disclosed |
| EP-3716975-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | Eiger Biopharmaceuticals, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| CN-111386115-A | Methods and pharmaceutical compositions for treating non-alcoholic steatohepatitis | 艾格尔峰生物制药有限公司 | 2020-07-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369693-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | FABP1, PYGL, PPARA | MAPK14 4378/4885FGFR1 323/4885CHRM2 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.